The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

Subscribe Play latest Open in podnodRSS feed Show website

24 episodes
Updated Yesterday

Episodes24

Newest first

Yesterday · 12 min
Week in Review | Takeda's Orzeyful Approval Opens the Orexin Market — and a Payer Fight
FDA approved Takeda's Orzeyful, a first-in-class orexin-2 agonist for narcolepsy type 1, with peak sales seen near $2B. Also: Replimune's Tudriqev wins accelerated approval with Opdivo in advanced melanoma after two rejections, Lantheus agrees to an up to $8.0 billion merger with Curium in radiopharmaceuticals, Tarsus buys Alkeus and its Stargardt disease candidate gildeuretinol for up to $800 million, reported AstraZeneca-Bristol Myers Squibb merger talks are denied, and LifeMine raises $263 million for a next-generation transplant immunosuppressant. Visit us at thepharmacloseout.com.
Saturday · 9 min
Daily Roundup | Vedanta's $60M Lifeline: What VE303 Must Prove in C. diff Phase 3
Vedanta Biosciences raised $60M, including $20M from BARDA, to finish the Phase 3 that decides its microbiome bet on VE303 in recurrent C. difficile infection. Plus Replimune's Tudriqev wins accelerated FDA approval in advanced melanoma after two rejections, LifeMine Therapeutics raises $263M for a fungal-derived calcineurin inhibitor in organ transplant, Revolution Medicines reports more than 2,000 compassionate use prescriptions for pancreatic cancer drug daraxonrasib, and Insmed lifts Brinsupri guidance after a record quarter. Visit us at thepharmacloseout.com.
Friday · 11 min
Daily Roundup | Replimune Wins FDA Approval for Melanoma Drug After Two Rejections
FDA approved Replimune's Tudriqev for advanced melanoma after two rejections - and over its own reviewers' written objections. Plus Moderna's mRNA flu vaccine mFlusiva clears for adults 50 and older with a split label, Iovance jumps 34% on record Amtagvi revenue and a 56% gross margin, and Tarsus buys Alkeus for up to $800 million for gildeuretinol in Stargardt disease. Melanoma, influenza, cell therapy and inherited retinal disease in a single Thursday. Visit us at thepharmacloseout.com.
Wednesday · 9 min
Daily Roundup | Merck's 2028 Keytruda Cliff: The Oral PCSK9 Bet
Merck posted $16.61B in Q2 revenue and $8.37B in Keytruda sales — then cut profit guidance on acquisition charges. Alex and Maya break down the oral PCSK9 approval, the planned sacituzumab tirumotecan and Keytruda combination trial, and what the 2028 loss of exclusivity forces next. Plus Pfizer's additional $2.5 billion in cost savings and Eliquis strength, the sigvotatug vedotin miss in non-small cell lung cancer, the Oxbryta write-down in sickle cell disease, and BioNTech naming Sobi's Guido Oelkers chief executive as it pivots toward oncology. Visit us at thepharmacloseout.com.
August 3 · 12 min
Daily Roundup | Curium Buys Lantheus for Up to $8B in Cash-and-CVR Deal
Curium will pay up to $8.0 billion for Lantheus — Asubstantial cash payment per share plus additional contingent value rights tied to milestones stretching out several years. We break down theradiopharmaceutical consolidation across PYLARIFY, DEFINITY and Neuraceq, the Supernus–Indivior all-stock merger creating a $2.2 billion CNS company spanningADHD, epilepsy, Parkinson's and opioid use disorder, and Amgen's cloud breachthat stole patient data and intellectual property. Plus the open biotech IPO window and Moderna's seasonal flu vaccine decision Wednesday. Visit us at thepharmacloseout.com.
August 3 · 11 min
Week in Review | AstraZeneca, Bristol Myers Squibb Weigh a $400B Merger
AstraZeneca and Bristol Myers Squibb held months of merger talks valuing the combined company near $400 billion, per the Financial Times — a deal that would make AstraZeneca the world's fourth-largest drugmaker and draw antitrust scrutiny over two overlapping oncology portfolios. Plus: MapLight's ML-007C-MA hit its Phase 2 schizophrenia endpoint and still lost two-thirds of its market value against Bristol Myers' Cobenfy, an FDA advisory committee voted down Capricor's deramiocel in Duchenne-related cardiomyopathy ahead of an August 22 decision, and Karyopharm's Xpovio failed a second Phase 3 in endometrial cancer. Eli Lilly's Q2 report and Moderna's mRNA-1010 flu vaccine decision both land August 5. Visit us at thepharmacloseout.com.
August 1 · 9 min
Daily Roundup | Novo Nordisk's ZEUS Failure: The Inflammation Thesis Just Got Repriced
Ziltivekimab missed its primary endpoint in the 6,300-patient Phase 3 ZEUS trial, sending Novo Nordisk down 10% and dragging BioAge Labs down 60% and Monte Rosa Therapeutics down 30%. Also: AbbVie's Skyrizi posts $5.5 billion in quarterly sales matching Humira's best quarter as J&J's Icotyde looms, Regeneron beats on Dupixent strength with Sanofi pledging to rebuild trust, Bristol Myers Squibb beats into its Revlimid and Eliquis patent cliff, Madrigal's Rezdiffra grows 71% in MASH, and IMPACT Therapeutics licenses senaparib to Pharmanovia. Visit us at thepharmacloseout.com.
July 31 · 10 min
Daily Roundup | Replimune Wins 10-3 FDA Panel Vote for Melanoma Drug RP1
An FDA advisory panel backed Replimune's RP1 by 10 to 3, overriding agency reviewers, with an approval decision due August 2nd. Also: the same-day panel voted Capricor's Duchenne cell therapy deramiocel down 9 to 3, Johnson & Johnson took a $2.58 billion option on Flagship's in vivo CAR-T biotech Sail Biomedicines, Pfizer's Litfulo hit both Phase 3 endpoints in vitiligo, Eli Lilly's $2.8 billion AtaiBeckley deal drew competing bidders in treatment-resistant depression, Alnylam fell 29% on Amvuttra, and the FTC sued Hims & Hers. Visit us at thepharmacloseout.com.
July 30 · 11 min
Daily Roundup | Capricor's Duchenne Cell Therapy Voted Down — What It Means for the Field
FDA advisers recommended against Capricor's deramiocel — and the stock had already lost up to 60% before the vote. Also: Replimune falls nearly 40% as FDA reviewers call RP1's melanoma survival data uninterpretable ahead of Thursday's panel; Biogen posts $2.7 billion and cuts EPS guidance on Apellis dilution as Leqembi, Spinraza and Skyclarys beat; AstraZeneca defends its $80 billion 2030 target and GSK bets its growth plan on oncology expansion; Vertex pays AbCellera $28 million upfront for autoimmune T-cell engagers; plus ProMIS in Alzheimer's, Atea in hepatitis C, and Altimmune in alcohol use disorder. Visit us at thepharmacloseout.com.
July 29 · 10 min
Daily Roundup | Replimune RP1 on the Brink: FDA Calls Melanoma Data Uninterpretable
FDA reviewers say Replimune's IGNYTE overall survival analysis is "not interpretable" days before Thursday's advisory committee — shares fell more than 32% to $5.78. We break down what it means for RP1, Opdivo combination therapy, and accelerated approval in advanced melanoma, plus Gossamer Bio reacquiring worldwide seralutinib rights from Chiesi ahead of a September NDA filing in pulmonary arterial hypertension, the FDA's parallel challenge to Capricor's Duchenne data, and IQVIA's second quarter earnings. Visit us at thepharmacloseout.com.
July 28 · 9 min
Daily Roundup | Capricor Craters 67% as FDA Questions Deramiocel Data
Capricor fell roughly 67% after FDA briefing documentsquestioned deramiocel's efficacy days before its advisory committee — and the company's rebuttal is a fight over which statistical analysis plan governs. Webreak down what that means for cell therapy in Duchenne muscular dystrophy, argenx's $2.2 billion all-cash acquisition of Forte Biosciences for the anti-CD122 antibody FB102 in vitiligo and celiac disease, and the abrupt CEO exit at Legend Biotech as competitive pressure builds around Carvykti. Visit us at thepharmacloseout.com.
July 26 · 13 min
Week in Review | Amgen Refuses to Pull Tavneos: FDA Showdown Lands Wednesday
Amgen told the FDA no — a blinded Duke re-analysis of ADVOCATE met noninferiority at 68.1% versus 67.1% but lost superiority, and the deadline is July 29. We unpack the avacopan withdrawal fight, the ChemoCentryx acquisition that bought it, and the EMA committee already moving against it. Plus Elevar's complete response letter for rivoceranib and camrelizumab in first-line liver cancer over a manufacturing inspection, Summit's ivonescimab survival update ahead of its November decision, Sun Pharma's $11.75 billion Organon approval, Scribe Therapeutics' gene editing IPO, Ipsen's Bylvay failure in biliary atresia, and the FDA peptide panel that voted yes on thin evidence. Visit us at thepharmacloseout.com
July 25 · 10 min
Daily Roundup | Novo Seeks Injunction on Lilly Obesity Ads: The Comparative Claims Precedent
Novo Nordisk is asking a court to shut down Eli Lilly'scomparative obesity ads — an injunction bid that could reset the rules for GLP-1 promotion industry-wide. Also: Sanofi ends amlitelimab development in atopic dermatitis, Ipsen's Bylvay fails the Phase 3 BOLD trial in biliary atresia, CHMP recommends NewAmsterdam Pharma and Menarini's obicetrapib and its ezetimibe combination in Europe, the FDA's peptide advisory panel splits itsvotes, Amgen fights to keep Tavneos on the market, Lilly moves to file retatrutide, and Arrowhead posts best-case triglyceride data. Visit us at thepharmacloseout.com.
July 24 · 13 min
Daily Roundup | J&J Bispecific Combo Cuts Myeloma Progression Risk 89%
J&J's Tecvayli–Talvey combo cut the risk of myeloma progression or death by 89% in earlier-line disease. Plus an FDA panel endorses wellness peptides including BPC-157, AstraZeneca's camizestran clears Europe in breast cancer, Repligen buys BioLife for $1.5B, BeOne's $300M reshoring push amid Trump's 200% generic tariff threat, Scribe's $129M gene-editing IPO, and Ipsen's Bylvay biliary atresia readout ahead. Visit us at thepharmacloseout.com.
July 23 · 13 min
Daily Roundup | GSK Wins First Lung Cancer Approval — Jideytro Validates a $10.6B Bet
GSK's Jideytro cleared the FDA two months early — a week after the $10.6B Nuvalent deal closed — for GSK's first lung cancer approval. Plus Arrowhead's plozasiran (Redemplo) posts best-case triglyceride and pancreatitis data against Ionis's Tryngolza, Summit's ivonescimab two-year NSCLC survival ahead of its November decision, Celldex's Phase 2 failure in prurigo nodularis, Sanofi's FDA untitled letter over Beyfortus and Pfizer's RSV vaccine, and Trump's 200% generic tariff countdown. Visit us at thepharmacloseout.com.
July 22 · 13 min
Daily Roundup | Novo Sues Lilly Over GLP-1 Ads: The Dose-Comparison Fight That Could Rewrite Obesity Marketing
Novo Nordisk sued Eli Lilly in federal court over "deceptive" ads comparing high-dose Zepbound and Mounjaro to lower-dose Wegovy and Ozempic. Also: Gilead and Merck back the first weekly oral HIV pill (islatravir/lenacapavir) with 48-week Phase 3 data, Novartis beats Q2 on Kisqali and Pluvicto as pelacarsen looms, Agios scraps sickle cell drug tebapivat, Dimension closes an $800M AI-biotech fund, Bristol Myers builds an NVIDIA AI supercomputer, and Amgen settles a $74M investor suit. Visit us at thepharmacloseout.com.
July 21 · 9 min
Daily Roundup | Tempus AI Buys Personalis for $1.5B in MRD Cancer Push
Tempus AI is buying Personalis for $1.5 billion, betting on cancer monitoring before reimbursement catches up. Plus Samsung Biologics' $1.8B all-cash bid for Swiss peptide maker PolyPeptide and its GLP-1 push, Legend Biotech's record Carvykti sales against a falling stock, Jennifer Doudna's Scribe Therapeutics CRISPR IPO, GSK shelving a $2B cough drug, Bristol Myers Squibb's Nvidia AI supercomputer, Takeda's dengue vaccine nod in India, and Novartis Fabhalta in IgA nephropathy. Visit us at thepharmacloseout.com.
July 19 · 15 min
Week in Review | GSK Kills Camlipixant: The P2X3 Cough Bet Just Went to Zero
GSK wrote off most of a $2 billion bet as camlipixantbecomes the third P2X3 antagonist to fail in chronic cough. Plus Lilly's $2.8B AtaiBeckley deal and July's IPO wave, Novartis Fabhalta's full approval in IgAN, Celcuity's Revtorpyk, Merck's oral PCSK9 pill and sac-TMT lung-cancerdata, the Jasper–Kira merger, and the Sanofi Sarclisa FDA decision ahead. Visit us at thepharmacloseout.com.
July 18 · 13 min
Daily Roundup | GSK Kills Camlipixant: The $2B Bellus Bet Unravels
GSK shelved camlipixant after mixed Phase 3 data — the third P2X3 chronic cough drug to fail and a blow to its ~$2B Bellus Health deal. Plus Jasper Therapeutics' lifeline merger with Kira and a $132M raise, Novartis Fabhalta's full FDA approval in IgA nephropathy, Lilly's $2.8B AtaiBeckley psychedelics buyout, a Merck ADC lung cancer readout, and a Pfizer downgrade. Visit us at thepharmacloseout.com.
July 16 · 10 min
Daily Roundup | Merck's Sac-TMT Beats Chemo in Lung Cancer — Keytruda's Cliff Answer
Merck's sac-TMT beat chemotherapy in first-line PD-L1-negative lung cancer — the emerging answer to Keytruda's patent cliff. Plus: Europe approves Novo Nordisk's oral Wegovy ahead of Eli Lilly, Sanofi sues Pfizer and Moderna over mRNA patents, Bora and Insilico Medicine ink a $2.5B AI alliance, the FDA resumes publishing complete response letters, Q32 Bio surges on alopecia areata data, and Veradermics posts a Phase 2 win in female pattern hair loss. Visit us at thepharmacloseout.com.

The Pharma Closeout | Daily Pharmaceutical &amp; Biotech News in 15 Minutes

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes